Uribe M, Farca A, Márquez M A, Garcĭa-Ramos G, Guevara L
Gastroenterology. 1979 Jun;76(6):1347-51.
A randomized double-blind clinical comparison of bromocriptine, a new dopamine agonist, and placebo was performed on 7 cirrhotic patients with chronic portal systemic encephalopathy (PSE). Before given either medication, patients were stabilized with a standard treatment (neomycin and cathartics). Serial semiquantitative assessments were done, including mental state, asterixis, number connection test, electroencephalogram, and ammonia blood levels. Three patients developed signs of precoma while ingesting both placebo and bromocriptine. Two patients experienced precoma only with placebo, and another patient only while taking bromocriptine. One patient remained awake throughout the study. All patients responded initially to neomycin and cathartics. Bromocriptine proved not to be significantly superior to placebo and was always inferior to standard treatment. During treatment with bromocriptine, 3 patients experienced constipation. This may be partially responsible for the ineffectiveness in the treatment of PSE.
对7例患有慢性门体性脑病（PSE）的肝硬化患者进行了一项随机双盲临床对照试验，比较新型多巴胺激动剂溴隐亭与安慰剂的疗效。在给予任何一种药物之前，患者均采用标准治疗（新霉素和泻药）使其病情稳定。进行了一系列半定量评估，包括精神状态、扑翼样震颤、数字连接试验、脑电图和血氨水平。3例患者在服用安慰剂和溴隐亭时均出现了昏迷前期症状。2例患者仅在服用安慰剂时出现昏迷前期，另1例患者仅在服用溴隐亭时出现。1例患者在整个研究过程中一直保持清醒。所有患者最初对新霉素和泻药均有反应。结果表明，溴隐亭并不显著优于安慰剂，且始终不如标准治疗有效。在服用溴隐亭治疗期间，3例患者出现便秘。这可能是溴隐亭治疗PSE无效的部分原因。
